Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Lifeactive Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is under review by 1 distinct examiner in 1 distinct art unit, showing a concentrated prosecution profile for the company's current filings. This indicates that the active portfolio is currently limited to a single technical application or a very specific area within the biotechnology sector.
The busiest examiner, CONIGLIO, AUDREA JUNE BUCKLEY, is assigned 1 busiest examiner pending office action. This indicates that the 1 pending office action is the sole focus of the company's current interactions with the patent office. For a practitioner, this concentration simplifies the management of the portfolio, as all active legal efforts are directed toward a single individual and a single art unit.
In the Biotechnology & Pharmaceuticals field, having only 1 distinct examiner involved allows for a very direct prosecution strategy. With 1 pending office action total, the workload is minimal, and the practitioner can focus entirely on the specific concerns of CONIGLIO, AUDREA JUNE BUCKLEY. This singular focus on 1 busiest examiner pending office action provides a clear and uncomplicated path for resolving the company's current patent matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CONIGLIO, AUDREA JUNE BUCKLEY | 1 | 53.1% | +20.6% |
| PACKARD, BENJAMIN J | 1 | 66.9% | +15.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18942968 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | CONIGLIO, AUDREA JUNE BUCKLEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18942968 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | CONIGLIO, AUDREA JUNE BUCKLEY | — |
| 18942965 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | PACKARD, BENJAMIN J | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18942968 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | CONIGLIO, AUDREA JUNE BUCKLEY | 1617 | §103§112 | Non-Final OA | — | Pending | Nov 11, 2024 |
| 18942965 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | PACKARD, BENJAMIN J | 1612 | §103DP | Non-Final OA | — | Pending | Nov 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLifeactive Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Audrea June Buckley Coniglio has the most, with 1 of Lifeactive Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
